← Leaderboards
Chetan N Shenoy
University Of Minnesota
$2,628,221
Attributed
$3,984,962
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $787.3K · FY2016–25$1M$750K$500K$250K$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,984,962 · 4
By mechanism
R01$2,713,482 · 1
K23$883,980 · 1
R21$232,500 · 1
R03$155,000 · 1
Top collaborators
- Jason V Baker4 shared
Most similar at University Of Minnesota
Same institution · by research overlap
- Maneesh Bhargava$3,198,107
- Gulin Oz$11,194,752
- Yasuhiko Kawakami$4,236,914
- Takako Araki$602,950
- Maxim Chacko-Joseph Cheeran$2,079,355
Others in their field
Top investigators on “Cardiovascular System”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Chanza Baytop · Westat, Inc.$271,217,917
- Judith S. Currier · University Of California Los Angeles$139,907,800
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$137,892,773
- Judith S Hochman · New York University School Of Medicine$110,228,771
Research focus
Cardiovascular SystemCardiacAcuteCardiomyopathiesHeart DiseasesRisk StratificationTroponinPatient StratificationUniversitiesMyocardialHeart FailureInjuryMortalityPathologyCoronary FibrosisPatient-Focused OutcomesCohortMinnesotaCardiologyFundingFunctional DisorderBaseCardiac Magnetic Resonance ImagingInfection
Grant awards (13)
Immunologic basis of cardiac disease after severe COVID-19$662,793
R01 · FY2025 · HL · contact PI
A Myocardial Approach to Identify the Cause of Cardiomyopathy$116,250
R21 · FY2025 · HL · contact PI
Immunologic basis of cardiac disease after severe COVID-19$671,068
R01 · FY2024 · HL · contact PI
A Myocardial Approach to Identify the Cause of Cardiomyopathy$116,250
R21 · FY2024 · HL · contact PI
Immunologic basis of cardiac disease after severe COVID-19$685,031
R01 · FY2023 · HL · contact PI
Immunologic basis of cardiac disease after severe COVID-19$694,590
R01 · FY2022 · HL · contact PI
Cardiac Magnetic Resonance Imaging Guided Risk Stratification in Cardiac Sarcoidosis$77,500
R03 · FY2022 · HL · contact PI
Cardiac Magnetic Resonance Imaging Guided Risk Stratification in Cardiac Sarcoidosis$77,500
R03 · FY2021 · HL · contact PI
Cardiac Fibrosis and Risk Prediction in Cancer Treatment-Related Cardiotoxicity$176,796
K23 · FY2020 · HL · contact PI
Cardiac Fibrosis and Risk Prediction in Cancer Treatment-Related Cardiotoxicity$176,796
K23 · FY2019 · HL · contact PI
Cardiac Fibrosis and Risk Prediction in Cancer Treatment-Related Cardiotoxicity$176,796
K23 · FY2018 · HL · contact PI
Cardiac Fibrosis and Risk Prediction in Cancer Treatment-Related Cardiotoxicity$176,796
K23 · FY2017 · HL · contact PI
Cardiac Fibrosis and Risk Prediction in Cancer Treatment-Related Cardiotoxicity$176,796
K23 · FY2016 · HL · contact PI